Earnings Day Decoded, What Actually Mattered Across Six Biotech Prints
5/4/2026
The headline scoreboards always lie on biotech earnings days. Six prints rolled out today and the stories have nothing to do with the EPS surprise tags. Let me walk through what the tape actually said.
CRSP, The Real Story Was The $600M Convertible
CRISPR Therapeutics (CRSP) at $48.79 after the recent slide. The company filed its 10-Q today and the buried lead is a $600 million convertible notes offering. That is the third event in two weeks weighing on the stock.
The other two, the Q1 print itself which showed loss per share of negative 1.37 versus consensus negative 1.15, and revenue of just 0.86 million, a 97.8 percent year over year decline. And Regeneron getting approval for Otarmeni gene therapy that will be provided at no cost to qualifying US patients, which puts pricing pressure on Casgevy directly.
The bull case still has bones. Approximately 90 percent of US patients had reimbursed access to Casgevy as of year end 2025. Pricing agreement secured in Germany. Reimbursed access in UK, Italy, Austria, Denmark, Luxembourg, KSA, UAE, Kuwait. Zugo-cel expanded into new autoimmune indications. Multiple in vivo liver-directed programs advancing toward the clinic.
But the convertible at this price level dilutes hard. CEO Samarth Kulkarni divested 10,349 shares on March 16. Insiders collectively sold 51,828 shares in the prior three months. That is the read.
M&A Score 55, Above Average. Vertex partnership locks the Casgevy economics so a buyer would inherit the 60/40 split with VRTX getting the bigger share. Pipeline is long-dated and capital-intensive. Insider selling is a tell.
Growth Score 48, Below Average. Casgevy ramp is real but slow. Otarmeni free-to-patient model is a structural problem for the premium pricing thesis. Convertible dilution caps near-term upside.
Tag, Avoid for now. Wait for either Casgevy reaccelerated revenue print or in vivo data validation.
ORIC, Class Action Lawyers Smell Blood
ORIC Pharmaceuticals at around $9.44, market cap roughly 968 million. The Q1 print today is a non-event. The actual catalyst was March 31 when the company released rinzimetostat (ORIC-944) program update. The PRC2 inhibitor in metastatic castration resistant prostate cancer, in combination with darolutamide, showed 33 percent confirmed PSA50 response rate, with radiographic progression-free survival rates of 93, X, X percent at 3, 4, 5 month time points respectively. The combination matched a competitor in the same PRC2 class but did not beat it as best in class.
The stock fell 41 percent on that news. Then the legal vultures arrived. Pomerantz Law Firm and Bronstein Gewirtz are both investigating securities fraud claims as of late April.
This is exactly the pattern we battle Templar style. Class action mills launching investigations on any biotech that prints disappointing data. They are not protecting investors. They are extracting fees from the very companies whose stocks just dropped, which then comes out of remaining shareholder value. Anyone watching ORIC, ignore the legal noise. The actual question is whether ORIC-944 has differentiation in earlier prostate cancer settings, plus what ORIC-114 (EGFR exon 20) and ORIC-533 (CD73 inhibitor) print.
M&A Score 50, Moderate. Resistance-focused oncology platform with multiple shots on goal at sub-1B market cap is buyer-friendly construction. Drag is the rinzimetostat best-in-class miss. Founders Charles Sawyers and Richard Heyman are top-tier scientific names, but the lawsuit overhang has to clear before anyone buys.
Growth Score 42, Below Average. Pre-revenue, multiple late-stage assets but the lead just lost differentiation. Cash position fine. Standalone path now harder.
Tag, M&A Target with overhang. Watch ORIC-114 next, not the lawsuits.
BHVN, Beat Plus Stock Stuck Equals Bigger Problem
Biohaven beat Q1 by 11.54 percent. Stock barely moved. That tells you EPS does not drive this name.
The drag is the troriluzole CHMP rejection in February 2025 plus the prior Phase 3 OPTI failure. Stock is down to single digits or low teens from north of 26 in the 52 week range. The MoDE platform (BHV-1300 series) is the second leg, but it is early.
The market needs the next troriluzole pivotal US data and material progress on the MoDE platform to re-rate. Until then, beats and misses on consensus EPS are noise on a name where the story is binary catalyst and dilution risk.
M&A Score 58, Moderate. Vlad Coric and the Coric brothers built the original Biohaven and sold it to Pfizer for 11.6 billion. They have done the trade before. Remaining BHVN has Nurtec-adjacent assets plus the MoDE platform. Acquirable construction. Drag is the dilution history and pipeline failures.
Growth Score 45, Below Average. Multiple late stage shots but recent track record on pivotal data is weak. Capital structure overhang.
Tag, M&A Target watch. Need pivotal data clean print before re-rating.
BMRN, The Quietly Important M&A Print Of The Day
BioMarin reported Q1 revenue of 766 million and the EPS miss got the alert. The market shrugged it off because the company simultaneously announced completion of the Amicus Therapeutics acquisition. That move adds two new commercial assets to the BMRN portfolio, Galafold (migalastat for Fabry disease) and Pombility (cipaglucosidase alfa plus miglustat for Pompe disease).
Updated FY2026 revenue guidance to 3.825 billion to 3.925 billion, which is 20 percent growth at the midpoint. That is an acceleration story, not a deceleration. Enzyme therapies (Vimizim, Naglazyme, Brineura) up 6 percent year over year. BMN401 ENPP1 deficiency pivotal data expected in Q2. Voxzogo hypochondroplasia pivotal data also expected Q2.
This is the M&A Hunter setup right here. Big rare disease specialist just bought a smaller one and immediately raised guidance. The Amicus deal closing means the FOLD ticker is gone and the value transfers into BMRN. Worth watching for whether BMRN itself becomes a target now that it has a richer portfolio. Logical buyers, Sanofi (rare disease focus), Pfizer (post-Seagen rebuild), Novartis.
M&A Score 64, Above Average. Mature commercial portfolio, just-completed accretive M&A, multiple Q2 catalysts. Drag is mid-cap size (around 14 billion) keeps it inside our framework window per the calibration rule.
Growth Score 72, High. Voxzogo international launches. New Galafold and Pombility revenue streams. BMN401 and Voxzogo hypochondroplasia data Q2. Real reacceleration story.
Tag, Dual Catalyst. Both scores above 60 with active catalysts. Best read on this name in two years.
TWST, AI Workflow Demand Is The Real Story
Twist Bioscience at 57.08, down 5.49 percent on the print. The headline says EPS missed by 11.32 percent. The actual Q2 fiscal 2026 numbers, revenue 110.7 million up 19 percent year over year, beat consensus and beat their own guidance of 107 to 108 million. Thirteenth consecutive quarter of sequential revenue growth.
The story underneath, DNA Synthesis and Protein Solutions revenue grew 28 percent to 53.3 million driven by AI-enabled drug discovery demand. Twist was named a wet lab partner for Amazon Bio Discovery. NGS Applications grew 12 percent to 57.4 million and management said NGS returns to at least 20 percent growth by Q4. Gross margin improved to 51.6 percent from 49.6 percent. Adjusted EBITDA loss narrowed to 13.3 million. Management reiterated they are firmly on track for adjusted EBITDA breakeven in Q4 fiscal 2026.
This is a real synbio acceleration story. The miss on EPS is largely 7.2 million in litigation charges plus elevated SG&A as the company invests in commercial and digital. Strip those out and the trajectory is clean.
The risk is cash fell to 171.7 million. They are not at imminent dilution risk but the runway needs the Q4 EBITDA breakeven to hit on time.
M&A Score 60, Above Average. AWS partnership is a strategic asset. AI workflow leverage is the right tape. Founder Emily Leproust is a category-defining CEO. Drag is the litigation overhang and the size (around 3.7B market cap with 80 percent IRR YTD on the run-up before today).
Growth Score 75, High. AI-driven demand acceleration. New product introductions on the semiconductor-based platform. EBITDA breakeven path visible. NGS reacceleration in Q4.
Tag, Growth Play. Higher Growth than M&A score. Hold the ramp.
PLSE, The Quiet Bottom Of The List
Pulse Biosciences at around 20, gained on the day despite the earnings miss alert. Pre-commercial nano-pulse field therapy company. Pre-revenue. EPS miss is academic when there is no revenue to miss against. The reason the stock can rally on a miss is the catalyst calendar matters more than the EPS line.
Watch for FDA strategy on AFib, partnership chatter on the cardiac surgery angle, and any pivotal trial design updates. Until those land, the name is lottery ticket construction.
M&A Score 45, Below Average. Pre-revenue device names rarely get acquired before pivotal data. Robert Duggan is the founder and has been here before with Pharmacyclics, that is the only reason the score is not lower.
Growth Score 40, Below Average. Pre-revenue, pre-pivotal. Long road.
Tag, Wait. Need clinical data print before this gets interesting.
The Day In One Read
Six earnings prints. One real M&A event (BMRN closing Amicus). One real dilution event (CRSP convertible). One real growth print (TWST AI demand). Three names where the EPS line is meaningless (ORIC, BHVN, PLSE).
Headlines lied today. As they do most earnings days.